Robert S. Boger

77 year

Health Technology

Profile

Robert S.
Boger was appointed Director of Drug Safety for GTx, Inc. on January 20, 2005 and had been Director of Clinical Development since May 2003.
From 1997 to January 2002, he was Director of Clinical Research for Transplantation and Immunology of Novartis Pharmaceuticals and Director of Medical Research and Clinical Science Leader of Roche's CellCeptTransplant Program from 1996 to 1997.
Dr. Boger was an Associate Director of Clinical Research and Medical Director of Renin Inhibitor Venture for Abbott Laboratories.
He received a BA degree in Biophysics from Amherst College and an MD from the Harvard Medical School.

Former positions of Robert S. Boger

Companies	Position	End
GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	Corporate Officer/Principal	-

See the detail of Robert S. Boger's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies